Get the Stockscreener App
2.0689
0.49%
0.0189
Telomir Pharmaceuticals Inc stock is traded at $2.0689, with a volume of 323.22K.
It is up +0.49% in the last 24 hours and up +64.80% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$2.05
Open:
$2.02
24h Volume:
323.22K
Relative Volume:
0.12
Market Cap:
$61.51M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-4.685
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+64.80%
6M Performance:
-54.42%
1Y Performance:
-45.93%
1-Day Range:
$2.00
$2.15
1-Week Range:
$2.00
$2.44
52-Week Range:
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.0667 | 64.81M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.17 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.51 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
344.20 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
605.20 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
302.15 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Real time social sentiment graph for Telomir Pharmaceuticals Inc.Free Entry Plan for Oversold Reversal Stocks - Newser
Technical analysis overview for Telomir Pharmaceuticals Inc. stockFree Weekly Top Gainers Forecast Watchlist - Newser
Chart Analysts Warn of Resistance Near Telomir Pharmaceuticals Inc. PriceHigh Yield Stock Screening Results Explained - metal.it
Top Risks to Consider Before Buying Telomir Pharmaceuticals Inc. StockFree Pattern Breakout Entry Stock Forecast - Newser
Will Telomir Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsFree Intraday Trend Analysis for Fast Gains - Newser
What makes Telomir Pharmaceuticals Inc. stock price move sharplyAI Trading Forecast Based on Big Data - Newser
Visual trend scoring systems applied to Telomir Pharmaceuticals Inc.Free Oversold Bounce Stock Play Ideas - Newser
Can volume confirm reversal in Telomir Pharmaceuticals Inc.Profitable Trading Blueprint with Entry Zones - Newser
Why is Telomir Pharmaceuticals Inc. stock attracting strong analyst attentionFree Stock Outlook That Work - jammulinksnews.com
Should I hold or sell Telomir Pharmaceuticals Inc. stock in 2025High-velocity gains - jammulinksnews.com
Is Telomir Pharmaceuticals Inc. meeting your algorithmic filter criteriaSwing Reversal Forecast Based on Patterns - Newser
How strong is Telomir Pharmaceuticals Inc. company’s balance sheetFree Daily Trading Room Entry - jammulinksnews.com
How volatile is Telomir Pharmaceuticals Inc. stock compared to the marketExplosive capital appreciation - jammulinksnews.com
Is it the right time to buy Telomir Pharmaceuticals Inc. stockInvest confidently with expert support - jammulinksnews.com
Published on: 2025-07-28 01:15:26 - jammulinksnews.com
When is Telomir Pharmaceuticals Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - jammulinksnews.com
Published on: 2025-07-27 20:33:38 - jammulinksnews.com
Telomir Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveLow Risk ROI Maximization - Newser
Competitive Positioning of Telomir Pharmaceuticals Inc.: Is It Leading or LaggingTop Performing Low Risk Stocks - Newser
What analysts say about Telomir Pharmaceuticals Inc. stockFree Smart Trading Workshop - PrintWeekIndia
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathway - Lansing State Journal
What drives Telomir Pharmaceuticals Inc. stock priceUnstoppable profit momentum - PrintWeekIndia
When is the best time to buy Telomir Pharmaceuticals Inc. stockSuperior risk-adjusted returns - jammulinksnews.com
Telomir Pharmaceuticals stock surges on promising Progeria treatment results - Investing.com
Telomir Pharmaceuticals stock surges on promising Progeria treatment results By Investing.com - Investing.com India
Telomir Pharmaceuticals announces new preclinical data on Telomir-1 - TipRanks
Telomir-1 shows promise in restoring mitochondrial function By Investing.com - Investing.com India
Telomir-1 shows promise in restoring mitochondrial function - Investing.com Australia
Revolutionary Mitochondrial Drug Could Transform Treatment of Alzheimer's, Parkinson's, and ALS - Stock Titan
Telomir Pharmaceuticals Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional
Telomir Pharmaceuticals Inc (NASDAQ: TELO) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Telomir Pharmaceuticals Inc (TELO) Stock: A Year of Stock Market Dynamics - investchronicle.com
Is Telomir Pharmaceuticals Inc. a good long term investmentExceptional trading results - jammulinksnews.com
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):